Pricing Log in Create free account
Friday 6 November 2026 Export PTCT’s income statement to Excel — free account

PTC Therapeutics, Inc.

PTCT Healthcare Biotechnology

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.

Revenue
+69.6%
EPS
−409.7%
Free cash flow
+90.3%
Total debt
+19.3%

Quarter to September 2026, against a year earlier

65.55 0.12 −0.18%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
42.2×
Dividend yield
—
F-score
7/9
Altman Z
1.86
Beneish M
−1.48
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 44.23
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 5 16 8 5 4 3 6 5 4 3 4 —
Insider Ownership 3.03%

Capital & Financial Ratios $m

Size
Market Cap 5,490.00
Revenue ttm 1,155.55
Net income ttm (105.97)
Free cash flow ttm (259.16)
Net debt Q 713.95
Valuation
P/E 0.00
Forward P/E 42.20 (above 35: high)
Price / sales 4.74
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 3.27 (at or above 1.5: strong)
Debt / equity Q (14.86) (negative: negative equity)
Interest coverage Q 0.55
Growth
Revenue growth Q +69.57% (above 0%: growing)
Operating income growth Q +732.69% (above 0%: growing)
EPS, this year −93.24% (below 0%: weak)
EPS, next year A +418.98% (at or above 15%: strong)
Revenue, next year A −24.19% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −17.42% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.4×, against a ten-year median of 5.6×; over the ten years it ranged from 0.3× in 2016 to 15.1× in 2016.
P/S against its own 10 years 37.35%
10-year low 10-year high
EV/Sales against its own 10 years 44.24%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 877 1,140 1,945 2,128
Receivables 161 159 182 238
Inventory 31 23 80 109
Other — — — —
1,219 1,366 2,274 2,538
2023 2024 2025 Q'26
Payables 392 304 381 441
ST’ Debt 194 258 570 319
Other — — — —
603 581 968 776

Compound Annual Growth %

10y 5y 3y
Sales 46.99% 35.37% 35.30%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.17 Actual 0.61

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.21 −1.67 Miss by 1.46
Q1 FY26 −0.45 −0.03 Beat by 0.42
Q2 FY26 −0.17 0.92 Beat by 1.09
Q3 FY26 0.17 0.61 Beat by 0.44
Q4 FY26 −0.05 — Reports 18 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.03) 0.92 (0.62) — —
’25 10.04 (0.83) 0.20 (1.67) 7.78
’24 (1.20) (1.29) (1.39) (0.85) (4.73)
’23 (1.88) (2.66) (1.76) (2.06) (8.37)
’22 (1.78) (2.13) (1.53) (2.35) (7.79)
’21 (1.83) (1.68) (1.89) (2.03) (7.43)
’20 (1.81) (2.78) (1.03) (1.08) (6.64)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 273 361 358 — —
’25 1,176 179 211 165 1,731
’24 210 187 197 213 807
’23 220 214 197 307 938
’22 149 166 217 167 699
’21 118 117 139 165 539
’20 68 75 118 119 381
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (59) 129 (25) — —
’25 870 (58) (66) (34) 711
’24 71 (71) (77) (30) (108)
’23 (29) (14) (15) (100) (158)
’22 (97) (55) (38) (166) (357)
’21 (100) (31) (51) (69) (251)
’20 (82) (75) 27 (64) (194)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (60) 122 (31) — —
’25 868 (62) (322) (37) 702
’24 6 (36) (143) (37) (154)
’23 (73) (33) (90) (129) (279)
’22 (179) (73) (64) (193) (509)
’21 (120) (39) (99) (93) (337)
’20 (99) (77) (2) (83) (250)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 83 194 265 307 381 539 699 938 807 1,731 1,156 +40.2% 1,312 1,407 1,621 (2.2%)
Gross margin, % 100.00 97.65 95.21 96.05 95.03 94.00 93.61 93.02 92.89 97.28 93.20 (2.7) pt
EBT (142) (78) (128) (240) (403) (518) (587) (696) (363) 697 (85) n/m
EBT margin, % (171.14) (39.95) (48.39) (78.16) (105.82) (96.24) (84.07) (74.23) (45.01) 40.25 (7.36) +211.4 pt
Net income (142) (79) (128) (252) (438) (524) (559) (627) (363) 683 (106) n/m
Per share, $
Per share, $ Revenue 2.43 4.96 5.68 5.22 5.77 7.64 9.74 12.53 10.50 21.76 13.84 +27.6%
Earnings (4.17) (2.02) (2.75) (4.27) (6.64) (7.43) (7.79) (8.37) (4.73) 8.58 (1.31) n/m
Cash flow (3.04) (0.26) (0.59) (1.68) (2.94) (3.57) (4.97) (2.12) (1.40) 8.94 0.13 n/m
Capex (0.05) (2.05) (0.33) (0.77) (0.85) (1.21) (2.13) (1.61) (0.60) (0.11) (3.23) +8.7%
Free cash flow (3.09) (2.31) (0.93) (2.45) (3.79) (4.78) (7.10) (3.73) (2.00) 8.83 (3.10) n/m
Book value 3.51 3.99 7.53 10.10 7.30 0.02 (4.84) (10.94) (14.29) (2.58) (2.29) n/m
Shares, m 34 39 47 59 66 70 72 75 77 80 82 +9.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.64 0.00 0.9
P/S 4.62 3.52 6.04 9.21 10.58 5.21 3.92 2.24 4.30 3.49 4.74 5.3
P/B 3.20 4.37 4.56 4.76 8.36 1,951.79 0.00 0.00 0.00 0.00 0.00 197.7
EV/Sales 3.01 3.28 5.76 8.00 10.34 5.98 5.26 3.56 5.84 3.87 5.35 5.5
EV/FCF (2.36) (48.47) (43.87) (16.52) (14.43) (8.86) (7.22) (10.25) (20.35) 15.10 (23.87) (15.7)
Cash, $m
Cash, $m Operating cash flow (104) (10) (28) (99) (194) (251) (357) (158) (108) 711 10 n/m
Capex (2) (80) (16) (45) (56) (85) (152) (121) (46) (9) (270) +19.4%
Free cash flow (105) (90) (43) (144) (250) (337) (509) (279) (154) 702 (259) n/m
Balance, $m
Balance, $m Working capital 212 167 154 543 954 445 288 616 785 1,306 1,762 +22.4%
Net debt (133) (46) (75) (373) (92) 412 938 1,239 1,243 653 714 n/m
Shareholders’ equity 120 156 351 594 482 1 (347) (819) (1,098) (205) (191) n/m
Returns, %
Returns, % ROA (44.79) (23.90) (16.95) (18.34) (22.87) (25.27) (30.68) (34.80) (20.18) 29.66 (3.62) +74.4 pt
ROIC 0.00 (36.48) (26.18) (68.01) (69.14) (56.59) (47.36) (65.37) (130.42) 121.13 17.66 +121.1 pt
ROE (82.24) (57.24) (50.51) (53.24) (81.42) (216.75) 323.46 107.51 37.91 (104.75) 61.08 (22.5) pt
People
People Employees 304 373 517 761 967 1,177 1,410 995 939 991 — +14.0%
Revenue/emp, $m 0.27 0.52 0.51 0.40 0.39 0.46 0.50 0.94 0.86 1.75 — +22.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

PTC Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MIRM Mirum Pharmaceuticals, Inc. $6.1B — (loss-making) — (loss-making) +39.63% (above 0%: growing) n/m −114.22% (below 0%: shrinking) 81.06% (32.17%) Compare
IMVT Immunovant, Inc. $5.9B — (loss-making) — — n/m −5.96% (below 0%: shrinking) 0.00% 0.00% Compare
BLTE Belite Bio, Inc. Sponsored ADR $5.8B — (loss-making) — — n/m +64.67% (above 0%: growing) — 0.00% Compare
CGON CG Oncology, Inc. $5.7B — (loss-making) — (loss-making) +2,125.00% (above 0%: growing) n/m −67.60% (below 0%: shrinking) (239.24%) (7,467.68%) Compare
KOD Kodiak Sciences Inc. $5.7B — (loss-making) — — n/m −33.86% (below 0%: shrinking) 0.00% 0.00% Compare
SRRK Scholar Rock Holding Corporation $5.5B — (loss-making) — (loss-making) +605.03% (above 0%: growing) n/m +8.88% (above 0%: growing) 0.00% 0.00% Compare
PTCT PTC Therapeutics, Inc. $5.5B — (loss-making) 42.2× +69.57% (above 0%: growing) n/m +90.28% (above 0%: growing) 93.39% 7.02%
MANE Veradermics Incorporated $5.4B — (loss-making) — — n/m −8.81% (below 0%: shrinking) — 0.00% Compare
COGT Cogent Biosciences, Inc. $5.1B — (loss-making) — (loss-making) −69.41% (below 0%: shrinking) n/m −42.01% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $5.7B — — +322.33% — −21.33% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 20 April 2026

Ownership

Directors and executive officers, together 5.30%
BlackRock, Inc. 14.40%
The Vanguard Group, Inc. 10.00%
RTW Investments L.P. 9.00%
Janus Henderson Group plc 5.90%
State Street Corporation 5.10%
The Toronto-Dominion Bank 5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

PTC Therapeutics, Inc. (PTCT) Latest News

31 Oct

Impact 3 · · Simply Wall St.

30 Oct

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby
Impact 3 · · Simply Wall St.

29 Oct

Impact 4 · · MarketBeat
Impact 4 · · Zacks
Impact 4 · · PR Newswire
Impact 3 · · Zacks
Impact 3 · · Associated Press

22 Oct

Impact 3 · · Zacks

21 Sep

Impact 4 ·

20 Sep

Impact 3 ·

24 Aug

Impact 4 ·
Impact 3 ·

16 Aug

Impact 4 · · MarketBeat

13 Aug

Impact 4 · · biopharmadive.com

12 Aug

Impact 4 ·

31 Jul

Impact 4 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·

30 Jul

Impact 3 ·

11 Jul

Impact 3 ·

2 Jul

Impact 3 ·

17 Jun

Impact 4 ·

7 Jun

Impact 4 · · Simply Wall St.

22 May

Impact 3 · · Zacks
Impact 3 · · Zacks

8 May

Impact 4 · · Moby
Impact 3 · · MarketBeat

7 May

Impact 4 · · Zacks

PTCT metrics, ten years each

stockrow.com/PTCT · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com